Zai Lab Appoints New Chief Medical Officer

TL;DR

Zai Lab just hired a new CMO, Dr. William Lu, effective immediately. Big move for their drug pipeline.

AI Summary

Zai Lab Ltd. announced on June 18, 2024, the appointment of Dr. William Lu as Chief Medical Officer and Executive Vice President, effective immediately. Dr. Lu brings extensive experience in clinical development and medical affairs, previously holding leadership roles at other pharmaceutical companies. This appointment is part of Zai Lab's ongoing efforts to strengthen its leadership team as it advances its drug pipeline.

Why It Matters

The appointment of a new Chief Medical Officer can signal a strategic shift or acceleration in the company's drug development pipeline, potentially impacting future clinical trial progress and regulatory approvals.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially in medical roles, can introduce uncertainty regarding strategic direction and execution of clinical development plans.

Key Players & Entities

• Zai Lab Ltd. (company) — Registrant
• Dr. William Lu (person) — Appointed Chief Medical Officer and Executive Vice President
• June 18, 2024 (date) — Effective date of appointment

FAQ

Key Financial Figures

• $0.000006 — resenting 10 Ordinary Shares, par value $0.000006 per share ZLAB The Nasdaq Global Market

Filing Documents

• zlab-20240618.htm (8-K) — 114KB
• exhibit1012024equityincent.htm (EX-10.1) — 137KB
• 0001628280-24-028764.txt ( ) — 447KB
• zlab-20240618.xsd (EX-101.SCH) — 2KB
• zlab-20240618_def.xml (EX-101.DEF) — 16KB
• zlab-20240618_lab.xml (EX-101.LAB) — 27KB
• zlab-20240618_pre.xml (EX-101.PRE) — 16KB
• zlab-20240618_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 18, 2024, the Company held its 2024 Annual Meeting. Holders of a total of 783,717,424 ordinary shares of the Company, constituting more than one-tenth of all voting share capital of the Company in issue as of the record date of April 25, 2024, were present in person (either physically or by virtual attendance) or by proxy at the Annual Meeting. The matters set forth below were voted on by the Company's shareholders at the Annual Meeting. Detailed descriptions of each proposal and the applicable voting procedures are contained in the Proxy Statement. Proposals 1 to 12, 14, and 16-17 in the notice of the Annual Meeting were approved at the Annual Meeting. For Proposal 13, the Company's shareholders voted on an advisory basis on the compensation of the named executive officers, as disclosed in the Proxy Statement. As Proposal 14 was carried as an ordinary resolution, Proposal 15 is not applicable. The final voting results for each matter submitted to a vote of shareholders at the Annual Meeting are as follows: Proposal 1 : (1) AS AN ORDINARY RESOLUTION: to re-elect Samantha (Ying) Du to serve as a director until the 2025 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal. For Against Abstentions Broker Non-Votes 766,937,519 14,985,985 1,793,920 - Accordingly, Proposal 1 was carried as an ordinary resolution. Proposal 2 : (2) AS AN ORDINARY RESOLUTION: to re-elect Kai-Xian Chen to serve as a director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. For Against Abstentions Broker Non-Votes 630,062,057 152,990,347 665,020 - Accordingly, Proposal 2 was carried as an ordinary resolution. Proposal 3 : (3) AS AN ORDINARY RESOLUTION: to re-elect John D. Diekman to serve as a director until the

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1# Zai Lab Limited 2024 Equity Incentive Plan 104 The cover page of this report is formatted in Inline XBRL # Management contract or compensatory plan, contract, or arrangement

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZAI LAB LIMITED By: /s/ F. Ty Edmondson Name: F. Ty Edmondson Title: Chief Legal Officer and Corporate Secretary Date: June 18, 2024

View Full Filing

View this 8-K filing on SEC EDGAR